Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain

García‑Salido, A. (Alberto); Carlos-Vicente, J.C. (Juan Carlos) de; Belda-Hofheinz, S. (Sylvia); Balcells-Ramírez, J. (Joan); Slöcker-Barrio, M. (Maria); Leóz-Gordillo, I. (Inés); Hernández-Yuste, A. (Alexandra); Guitart-Pardellans, C. (Carmina); Cuervas‑Mons-Tejedor, M. (Maite); Huidobro-Labarga, B. (Beatriz); Vázquez-Martínez, J.L. (José Luís); Gutierrez-Jimeno, M. (Miriam); Oulego-Erróz, I. (Ignacio); Trastoy-Quintela, J. (Javier); Medina-Monzón, C. (Carmen); Medina-Ramos, L. (Laura); Holanda-Peña, M.S. (María Soledad); Gil‑Antón, J. (Javier); Sorribes-Ortí, C. (Clara); Flores-González, J.C. (José Carlos); Hernández-Palomo, R.M. (Rosa María); Sánchez-Ganfornina, I. (Inma); Fernández-Romero, E. (Emilia); García‑Besteiro, M. (María); López‑Herce-Cid, J. (Jesús); González-Cortés, R. (Rafael)

Keywords:

SARS-CoV-2
Pediatric multisystem infammatory syndrome temporally associated with COVID-19
Kawasaki disease
Toxic shock syndrome
Children
Critical care
Shock

Issue Date:

2020

Publisher:

Springer Nature

ISSN:

1364-8535

Note:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Citation:

García‑Salido, A. (Alberto); Carlos-Vicente, J.C. (Juan Carlos) de; Belda-Hofheinz, S. (Sylvia); et al. "Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain". Critical care. 24 (1), 2020, 666

Abstract

Background Multisystem inflammatory syndrome temporally associated with COVID-19 (MIS-C) has been described as a novel and often severe presentation of SARS-CoV-2 infection in children. We aimed to describe the characteristics of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS-C in comparison with those admitted with SARS-CoV-2 infection with other features such as COVID-19 pneumonia. Methods A multicentric prospective national registry including 47 PICUs was carried out. Data from children admitted with confirmed SARS-CoV-2 infection or fulfilling MIS-C criteria (with or without SARS-CoV-2 PCR confirmation) were collected. Clinical, laboratory and therapeutic features between MIS-C and non-MIS-C patients were compared. Results Seventy-four children were recruited. Sixty-one percent met MIS-C definition. MIS-C patients were older than non-MIS-C patients (p = 0.002): 9.4 years (IQR 5.5–11.8) vs 3.4 years (IQR 0.4–9.4). A higher proportion of them had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non-MIS-C patients presented more frequently with respiratory distress (60.7% vs 13.3%, p < 0.001). MIS-C patients showed higher prevalence of fever (95.6% vs 64.3%, p < 0.001), diarrhea (66.7% vs 11.5%, p < 0.001), vomits (71.1% vs 23.1%, p = 0.001), fatigue (65.9% vs 36%, p = 0.016), shock (84.4% vs 13.8%, p < 0.001) and cardiac dysfunction (53.3% vs 10.3%, p = 0.001). MIS-C group had a lower lymphocyte count (p < 0.001) and LDH (p = 0.001) but higher neutrophil count (p = 0.045), neutrophil/lymphocyte ratio (p < 0.001), C-reactive protein (p < 0.001) and procalcitonin (p < 0.001). Patients in the MIS-C group were less likely to receive invasive ventilation (13.3% vs 41.4%, p = 0.005) but were more often treated with vasoactive drugs (66.7% vs 24.1%, p < 0.001), corticosteroids (80% vs 44.8%, p = 0.003) and immunoglobulins (51.1% vs 6.9%, p < 0.001). Most patients were discharged from PICU by the end of data collection with a median length of stay of 5 days (IQR 2.5–8 days) in the MIS-C group. Three patients died, none of them belonged to the MIS-C group. Conclusions MIS-C seems to be the most frequent presentation among critically ill children with SARS-CoV-2 infection. MIS-C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical ventilation than non-MIS-C patients.

URI:

https://hdl.handle.net/10171/67890

DOI:

10.1186/s13054-020-03332-4

Appears in Collections:

DA - CUN - Pediatría - Artículos de revista

Files in This Item: